Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.13 USD | -18.70% | -23.38% | +63.85% |
06-04 | LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License | CI |
05-15 | LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 644K 882K |
---|---|---|---|---|---|
Net income 2022 | -4M -5.48M | Net income 2023 | - 0 | EV / Sales 2022 | - |
Net cash position 2022 | 1.15M 1.57M | Net cash position 2023 | 2.04M 2.79M | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.05
x | P/E ratio 2023 |
1.91
x | Employees | 2 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.44% |
1 day | -18.70% | ||
1 week | -23.38% | ||
Current month | -22.83% | ||
1 month | -36.75% | ||
3 months | +20.34% | ||
6 months | +113.00% | ||
Current year | +63.85% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Snowdy
CEO | Chief Executive Officer | 55 | 22-01-09 |
John Caloz
DFI | Director of Finance/CFO | 72 | 07-09-30 |
Cristina Newman
SEC | Corporate Secretary | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Jennifer Simpson
CHM | Chairman | 55 | 21-07-28 |
Cary Claiborne
BRD | Director/Board Member | 64 | 22-07-26 |
Joel Caldwell
BRD | Director/Board Member | 69 | 17-07-11 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-18 | 2.13 | -18.70% | 365 |
24-06-17 | 2.62 | -5.07% | 1,260 |
24-06-14 | 2.76 | 0.00% | 198 |
24-06-13 | 2.76 | -0.72% | 729 |
24-06-12 | 2.78 | -1.17% | 614 |
Delayed Quote OTC Markets, June 18, 2024 at 02:14 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+63.85% | 1.05M | |
+34.01% | 51.07B | |
+34.55% | 38.61B | |
-8.02% | 38.78B | |
-8.98% | 27.32B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- LADX Stock